Johnson & Johnson (JNJ) vs Merck & Co., Inc. (MRK)
Johnson & Johnson and Merck & Co., Inc. are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $652.8B against $365.4B — 1.8× the size. Johnson & Johnson trades at the lower P/E: 31.4× against 119×. Johnson & Johnson grew revenue faster over the last twelve months: 8.06% against 4.64%. Johnson & Johnson has the higher net margin (21.5% vs 4.77%) and the higher return on invested capital (15.5% vs 5.08%). Both pay a dividend; Johnson & Johnson yields more (3.07% vs 2.58%). Across the 23 metrics below, Johnson & Johnson leads on 14 and Merck & Co., Inc. on 9.
Valuation
Profitability
| Metric | JNJ | MRK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 67.91% | 72.97% | 72.77% |
| Operating margin | 27.69% | 10.49% | 18.90% |
| Net margin | 21.48% | 4.77% | 8.27% |
| Free cash flow margin | 23.20% | 24.13% | 17.25% |
| Return on equity | 25.74% | 6.97% | 6.97% |
| Return on assets | 10.67% | 2.57% | 2.76% |
| Return on invested capital | 15.51% | 5.08% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack